Why I initiate therapy with two insulin sensitizers in patients with type 2 diabetes

Endocrine Practice

Volumn 9, Issue 1, 2003, Pages 98-100

  Bell, David S H ^a  

^a University of Alabama at Birmingham   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; C PEPTIDE; C REACTIVE PROTEIN; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN; LIVER TRIACYLGLYCEROL LIPASE; LOW DENSITY LIPOPROTEIN; METFORMIN; NONSTEROID ANTIINFLAMMATORY AGENT; PLASMINOGEN ACTIVATOR INHIBITOR 1; ROSIGLITAZONE; SELECTIVE ESTROGEN RECEPTOR MODULATOR; SULFONYLUREA; THIAZOLE DERIVATIVE; TRIACYLGLYCEROL; TROGLITAZONE;

ANEMIA; ANOREXIA; ARTICLE; BODY WEIGHT DISORDER; CONGESTIVE HEART FAILURE; DIARRHEA; DRUG EFFICACY; EDEMA; ENDOTHELIUM INJURY; ENZYME ACTIVITY; ENZYME INHIBITION; GASTROINTESTINAL SYMPTOM; HUMAN; HYPOGLYCEMIA; INSULIN RESISTANCE; INSULIN SENSITIVITY; MONOTHERAPY; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; WEIGHT GAIN;

EID: 0037484181     PISSN: 1530891X     EISSN: None     Source Type: Journal    
DOI: 10.4158/ep.9.1.98     Document Type: Article

References (27)

1. Bell DSH, Ovalle F. C-peptide utilization in clinical practice: effect on treatment and outcome of diabetes in a series of cases. Endocr Pract. 1999;5:114-118.
2. Brunzell JD, Hokanson JE. Dyslipidemia of central obesity and insulin resistance. Diabetes Care. 1999;22(Suppl 3):C10-C13.
3. Ovalle F, Bell DSH. Differing effects of thiazolidinediones on LDL and HDL subfractions and Lp(a) [abstract]. Diabetes. 2001;50(Suppl 2):A453-A454; A461-A462.
4. Steinberg HO, Chaker H, Leaming R, Johnson A, Brechtel G, Baron AD. Obesity/insulin resistance is associated with endothelial dysfunction: implications for the syndrome of insulin resistance. J Clin Invest. 1996;97: 2601-2610.
5. Fontbonne AM, Eschwege EM. Insulin and cardiovascular disease: Paris Prospective Study. Diabetes Care. 1991;14:461-469.
6. Despres JP, Lamarche B, Mauriege P, et al. Hyper-insulinemia as an independent risk factor for ischemic heart disease. N Engl J Med. 1996;334:952-957.
7. DeFronzo RA, Ferrannini E. Insulin resistance: a multi-faceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidemia, and atherosclerotic cardiovascular disease. Diabetes Care. 1991;14:173-194.
8. Weston WM, Heise MA, Porter LE, Bakris G, Viberti G, Freed MI. Rosiglitazone mediated reductions in urinary albumin excretion are associated with changes in ambulatory blood pressure in type 2 diabetes patient [abstract]. Diabetes. 2001;50(Suppl 2):A134.
9. Shimomura I, Funahashi T, Takahashi M, et al. Enhanced expression of PAI-1 in visceral fat: possible contributor to vascular disease in obesity. Nat Med. 1996;2: 800-803.
10. Sobel BE. The potential influence of insulin and plasminogen activator type 1 on the formation of vulnerable atherosclerotic plaques associated with type 2 diabetes. Proc Assoc Am Physicians. 1999;111:313-318.
11. Chu NV, Kong AP, Kim DD, et al. Differential effects of metformin and troglitazone on cardiovascular risk factors in patients with type 2 diabetes [erratum in Diabetes Care. 2002;25:947]. Diabetes Care. 2002;25:542-549.
12. McGill JB, Schneider DJ, Arfken CL, Lucore CL, Sobel BE. Factors responsible for impaired fibrinolysis in obese subjects and NIDDM patients. Diabetes. 1994;43:104-109.
13. Torzewski M, Rist C, Mortensen RF, et al. C-reactive protein in arterial intima: role of C-reactive protein receptor-dependent monocyte recruitment in atherogenesis. Arterioscler Thromb Vasc Biol. 2000;20:2094-2099.
14. Moharty P, Aljada A, Ghanim H, et al. Rosiglitazone improves vascular reactivity, inhibits oxygen species (ROS) generation, reduces P47 Phox subunit expression in mononuclear cells (MNC) and reduces C-reactive protein (CRP) and monocyte chemotactic protein 1 (MCP-1): evidence of a potent anti-inflammatory effect [abstract]. Diabetes. 2001;50(Suppl 2):A68.
15. Law RE, Goetze S, Xi VP, et al. Expression and function of PPARgamma in rat and human vascular smooth muscle cells. Circulation. 2000;101:1311-1318.
16. Minamikawa J, Tanaka S, Yamauchi M, Inoue D, Koshiyama H. Potent inhibitory effect of troglitazone on carotid arterial wall thickness in type 2 diabetes. J Clin Endocrinol Metab. 1998;83:1818-1820.
17. Takagi T, Akasaka T, Yamamuro A, et al. Troglitazone reduces neointimal tissue proliferation after coronary stent implantation in patients with non-insulin dependent diabetes mellitus: a serial intravascular ultrasound study. J Am Coll Cardiol. 2000;36:1529-1535.
18. Bell DSH, Ovalle F. Tissue triglyceride levels in type 2 diabetes and the role of thiazolidinediones in reversing the effects of tissue hypertriglyceridemia: review of the evidence in animals and humans. Endocr Pract. 2001;7:135-138.
19. Shimabukuro M, Ohneda M, Lee Y, Unger RH. Role of nitric oxide in obesity-induced beta cell disease. J Clin Invest. 1997;100:290-295.
20. Shimabukuro M, Zhou YT, Lee Y, Unger RH. Troglitazone lowers islet fat and restores beta cell function of Zucker diabetic fatty rats. J Biol Chem. 1998;273:3547-3550.
21. Finegood DT, McArthur MD, Kojwang D, et al. Beta cell mass dynamic in Zucker diabetic fatty rats: rosiglitazone prevents the rise in net cell death. Diabetes. 2001; 50:1021-1029.
22. Porter LE, Freed MI, Jones NP, Biswas N. Rosiglitazone improves beta cell function as measured by proinsulin/ insulin ratio in patients with type 2 diabetes [abstract]. Diabetes. 2000;49(Suppl 1):A122.
23. Ovalle F, Bell DSH. Clinical evidence of thiazolidinedione -induced improvement of pancreatic beta-cell function in patients with type 2 diabetes mellitus. Diabetes Obes Metab. 2002;4:56-59.
24. Bell DSH, Ovalle F. Long-term efficacy of triple oral therapy for type 2 diabetes mellitus. Endocr Pract. 2002;8:271-275.
25. Stratton IM, Adler AI, Neil HA, et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ. 2000;321:405-412.
26. Khaw KT, Wareham N, Luben R, et al. Glycated haemoglobin, diabetes, and mortality in men in Norfolk cohort of European Prospective Investigation of Cancer and Nutrition (EPIC-Norfolk). BMJ. 2001;322:15-18.
27. Bell DSH, Mayo MS. Weight loss in patients with diabetes treated with a metformin-sulfonylurea combination in comparison with twice-daily mixed insulin. Endocr Pract. 1998;4:360-364.